Ocular Therapeutix™ to Present at the H.C. Wainwright Global Life Sciences Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Apr 3, 2019--Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will give a company presentation on Monday, April 8, 2019 at 2:10 p.m. BST at the H.C. Wainwright Global Life Sciences Conference at the JW Marriott Grosvenor House in London, UK.
In addition to the presentation, the management team will host investor meetings at the conference. Investors attending the conference who are interested in meeting with Ocular Therapeutix management should contact their H.C. Wainwright representative.
A live webcast of the presentation can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com. A replay of the webcast will be available on the Company’s website for 90 days following the conclusion of the event.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is FDA-approved for the treatment of ocular pain following ophthalmic surgery. OTX-TP (intracanalicular travoprost insert) is an intracanalicular insert in Phase 3 clinical development for the reduction of intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension. The Company’s earlier stage assets include OTX-TIC, an extended-delivery intracameral travoprost implant for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal implants for the treatment of retinal diseases. These intravitreal implants include OTX-TKI, containing a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, OTX-IVT, an extended-delivery protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix’s first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190403005285/en/
CONTACT: InvestorsOcular Therapeutix
Chief Financial Officer
Westwicke, an ICR Company
Chris Brinzey, 339-970-2843
Senior Vice President, Commercia
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Ocular Therapeutix, Inc.
Copyright Business Wire 2019.
PUB: 04/03/2019 08:00 AM/DISC: 04/03/2019 08:01 AM